Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 15 May 2006, Vol. 107, No. 10, pp. 4071-4079.
Prepublished online as a Blood First Edition Paper on January 17, 2006; DOI 10.1182/blood-2005-08-3153.


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2005-08-3153v1
107/10/4071    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by YAMADA, Y.
Right arrow Articles by CANCELAS, J. A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by YAMADA, Y.
Right arrow Articles by CANCELAS, J. A
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Next Article next article arrow

Submitted August 5, 2005
Accepted January 7, 2006

The FIP1L1-PDGFR{alpha} fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease

YOSHIYUKI YAMADA, MARC E ROTHENBERG, ANDREW W LEE, HIROKO SAITO AKEI, ERIC B BRANDT, DAVID A WILLIAMS, and JOSE A CANCELAS*

Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
Division of Experimental Hematology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
Division of Experimental Hematology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA; Hoxworth Blood Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA

* Corresponding author; email: jose.cancelas{at}chmcc.org.

Dysregulated tyrosine kinase activity by the Fip-1-like 1 (FIP1L1)-platelet derived growth factor receptor alpha (PDGFR{alpha}) (F/P) fusion gene has been identified as a cause of clonal hypereosinophilic syndrome (HES), called F/P-positive chronic eosinophilic leukemia (CEL) in human. However, transplantation of F/P-transduced hematopoietic stem cells/progenitors (F/P+ HSC/P) into mice results in chronic myelogenous leukemia-like disease, which does not resemble HES. Because a subgroup of patients with HES show T-cell dependent interleukin-5 (IL-5) overexpression, we determined if expression of the F/P fusion gene in the presence of transgenic T-cell IL-5 overexpression in mice induces HES-like disease. Mice transplanted with CD2-IL-5 transgenic F/P+ HSC/P (IL-5Tg-F/P) developed intense leukocytosis, strikingly high eosinophilia and eosinophilic infiltration of non-hematopoietic as well as hematopoietic tissues, a phenotype resembling human HES. The disease phenotype was transferable to secondary recipients transplanted at a high cell dose, suggesting involvement of a short-term repopulating stem cell or an early myeloid progenitor. Induction of significant eosinophilia was specific for F/P since expression of another fusion oncogene, p210-BCR/ABL in the presence of IL-5 overexpression was characterized by a significantly lower eosinophilia than IL-5Tg-F/P recipients. These results suggest that F/P is not sufficient to induce a HES/CEL-like disease but requires a second event associated with IL-5 overexpression.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
BloodHome page
L. C. Kottyan, A. R. Collier, K. H. Cao, K. A. Niese, M. Hedgebeth, C. G. Radu, O. N. Witte, G. K. Khurana Hershey, M. E. Rothenberg, and N. Zimmermann
Eosinophil viability is increased by acidic pH in a cAMP- and GPR65-dependent manner
Blood, September 24, 2009; 114(13): 2774 - 2782.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. Fukushima, I. Matsumura, S. Ezoe, M. Tokunaga, M. Yasumi, Y. Satoh, H. Shibayama, H. Tanaka, A. Iwama, and Y. Kanakura
FIP1L1-PDGFR{alpha} Imposes Eosinophil Lineage Commitment on Hematopoietic Stem/Progenitor Cells
J. Biol. Chem., March 20, 2009; 284(12): 7719 - 7732.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. Cools
FIP1L1/PDGFR{alpha}'s Kit to stimulate mast cells
Blood, September 15, 2008; 112(6): 2179 - 2179.
[Full Text] [PDF]


Home page
BloodHome page
Y. Yamada, A. Sanchez-Aguilera, E. B. Brandt, M. McBride, N. J. H. Al-Moamen, F. D. Finkelman, D. A. Williams, J. A. Cancelas, and M. E. Rothenberg
FIP1L1/PDGFR{alpha} synergizes with SCF to induce systemic mastocytosis in a murine model of chronic eosinophilic leukemia/hypereosinophilic syndrome
Blood, September 15, 2008; 112(6): 2500 - 2507.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Buitenhuis, L. P. Verhagen, J. Cools, and P. J. Coffer
Molecular Mechanisms Underlying FIP1L1-PDGFRA-Mediated Myeloproliferation
Cancer Res., April 15, 2007; 67(8): 3759 - 3766.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020